Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials
Objectives Idiopathic pulmonary fibrosis (IPF) has been defined as a distinctive type of chronic fibrotic disease, characterised by a progressive decline in lung function and a common histological pattern of interstitial pneumonia. To analyse the efficacy and safety of pirfenidone in the treatment o...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/12/e050004.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136736118210560 |
|---|---|
| author | Wenjuan Wu Guojun Zhang Lingxiao Qiu Jizhen Wu Xueya Liu |
| author_facet | Wenjuan Wu Guojun Zhang Lingxiao Qiu Jizhen Wu Xueya Liu |
| author_sort | Wenjuan Wu |
| collection | DOAJ |
| description | Objectives Idiopathic pulmonary fibrosis (IPF) has been defined as a distinctive type of chronic fibrotic disease, characterised by a progressive decline in lung function and a common histological pattern of interstitial pneumonia. To analyse the efficacy and safety of pirfenidone in the treatment of IPF, a systematic review and meta-analysis was performed.Design This is a meta-analysis study.Participants Patients were diagnosed as IPF.Interventions Use of pirfenidone.Primary and secondary outcome Progression-free survival (PFS), acute exacerbation and worsening of IPF and Impact on adverse events.Measures The inverse variance method for the random-effects model was used to summarise the dichotomous outcomes, risk ratios and 95% CIs.Results A total of 9 randomised controlled trials with 1011 participants receiving pirfenidone and 912 controls receiving placebo were summarised. The pooled result suggested a statistically significant difference inall-cause mortality after pirfenidone use, with a summarised relative ratio of 0.51 (p<0.01). Longer PFS was observed in patients receiving pirfenidone compared with those who were given placebo (p<0.01). The IPF groups presented a high incidence of adverse events with a pooled relative ratio of 3.89 (p<0.01).Conclusions Pirfenidone can provide survival benefit for patients with IPF. Pirfenidone treatment was also associated with a longer PFS, a lower incidence of acute exacerbation and worsening of IPF. |
| format | Article |
| id | doaj-art-f83b9c26cbb547a4ab7f836bc892d3b8 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-f83b9c26cbb547a4ab7f836bc892d3b82024-12-08T14:25:09ZengBMJ Publishing GroupBMJ Open2044-60552021-12-01111210.1136/bmjopen-2021-050004Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trialsWenjuan Wu0Guojun Zhang1Lingxiao Qiu2Jizhen Wu3Xueya Liu4Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Geriatrics, Henan Provincial People`s Hospital, Zhengzhou, ChinaDepartment of Geriatrics, Henan Provincial People`s Hospital, Zhengzhou, ChinaObjectives Idiopathic pulmonary fibrosis (IPF) has been defined as a distinctive type of chronic fibrotic disease, characterised by a progressive decline in lung function and a common histological pattern of interstitial pneumonia. To analyse the efficacy and safety of pirfenidone in the treatment of IPF, a systematic review and meta-analysis was performed.Design This is a meta-analysis study.Participants Patients were diagnosed as IPF.Interventions Use of pirfenidone.Primary and secondary outcome Progression-free survival (PFS), acute exacerbation and worsening of IPF and Impact on adverse events.Measures The inverse variance method for the random-effects model was used to summarise the dichotomous outcomes, risk ratios and 95% CIs.Results A total of 9 randomised controlled trials with 1011 participants receiving pirfenidone and 912 controls receiving placebo were summarised. The pooled result suggested a statistically significant difference inall-cause mortality after pirfenidone use, with a summarised relative ratio of 0.51 (p<0.01). Longer PFS was observed in patients receiving pirfenidone compared with those who were given placebo (p<0.01). The IPF groups presented a high incidence of adverse events with a pooled relative ratio of 3.89 (p<0.01).Conclusions Pirfenidone can provide survival benefit for patients with IPF. Pirfenidone treatment was also associated with a longer PFS, a lower incidence of acute exacerbation and worsening of IPF.https://bmjopen.bmj.com/content/11/12/e050004.full |
| spellingShingle | Wenjuan Wu Guojun Zhang Lingxiao Qiu Jizhen Wu Xueya Liu Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials BMJ Open |
| title | Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials |
| title_full | Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials |
| title_fullStr | Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials |
| title_full_unstemmed | Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials |
| title_short | Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials |
| title_sort | efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients a systematic review and meta analysis of randomised controlled trials |
| url | https://bmjopen.bmj.com/content/11/12/e050004.full |
| work_keys_str_mv | AT wenjuanwu efficacyandsafetyofpirfenidoneinthetreatmentofidiopathicpulmonaryfibrosispatientsasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT guojunzhang efficacyandsafetyofpirfenidoneinthetreatmentofidiopathicpulmonaryfibrosispatientsasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT lingxiaoqiu efficacyandsafetyofpirfenidoneinthetreatmentofidiopathicpulmonaryfibrosispatientsasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT jizhenwu efficacyandsafetyofpirfenidoneinthetreatmentofidiopathicpulmonaryfibrosispatientsasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT xueyaliu efficacyandsafetyofpirfenidoneinthetreatmentofidiopathicpulmonaryfibrosispatientsasystematicreviewandmetaanalysisofrandomisedcontrolledtrials |